VISEN Pharmaceuticals (維昇藥業, stock code: 2561.HK) is an innovative biopharmaceutical company specializing in the development and commercialization of therapies for endocrine diseases in Greater China. Founded in 2018 as a spin-off from Ascendis Pharma, it holds exclusive rights to advance key products including lonapegsomatropin (a once-weekly long-acting growth hormone for pediatric growth hormone deficiency), navepegritide (TransCon CNP for achondroplasia), and palopegteriparatide (for chronic hypoparathyroidism).
Headquartered in Suzhou, China, with operations supporting R&D, manufacturing, and commercialization, VISEN collaborates with partners like WuXi Biologics on advanced microbial production. This includes technology transfer for lonapegsomatropin at WuXi's Chengdu site in Wenjiang District—a 95,000 m² facility featuring a 15,000 L fermenter (expandable to 60,000 L), vial-filling for over 10 million units annually, and China's first dual-chamber lyophilization line. Targeting GMP commercial release by end-2026, the site leverages the EffiX E. coli platform for high-yield protein expression and rapid CMC development.
Also known as 維昇藥業.
None yet. When a new project in the record names VISEN Pharmaceuticals as owner, partner or investor, it shows here.
Targeting GMP by end‑2026; 95,000 m² Chengdu site with 15,000 L fermenter (110 DS batches/yr, upgradable), dual‑chamber lyophilizer, >10M vials/yr fill, automation and green design
